Mumbai: Global pharma major Lupin Limited has announced that the API manufacturing facility of its wholly owned subsidiary, ...

Nazara Technologies' subsidiary Nodwin shareholding falls, Dixon's agreements with Chinese firms scrutinised, LT Foods opens ...

Lupin launches Loteprednol Etabonate Ophthalmic Suspension, 0.5%, a generic equivalent to Lotemax, for eye inflammation treatment.

Lupin today announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United States. Loteprednol Etabonate Ophthalmic Suspension, 0.5% is bioequivalent to Lotemax Ophthalmic ...

Mumbai: Global pharma major Lupin Limited has launched Loteprednol Etabonate Ophthalmic Suspension, 0.5%, in the United ...

Lupin announced that it has launched Loteprednol Etabonate Ophthalmic Suspension in the United States.

Blood derived treatment from two allogeneic sources for severe dry eye associated to keratopathy: a multicentre randomised cross over clinical trial ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

Amgen (AMGN) announced on Monday that a late-stage study evaluating its Bemarituzumab in combination with chemotherapy met its primary endpoint of improving overall survival. Bemarituzumab plus ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall ...